nach oben

Clinical Rheumatology

Erschienen in:

01.12.2013 | Review Article

Perspectives of the relationship between IL-7 and autoimmune diseases

verfasst von: Xiao-Song Wang, Bao-Zhu Li, Lin-Feng Hu, Peng-Fei Wen, Min Zhang, Hai-Feng Pan, Dong-Qing Ye

Erschienen in: Clinical Rheumatology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Interleukin (IL)-7 is one of the IL-2 family cytokines comprised of IL-2, IL-4, IL-7, IL-9, IL-15, as well as IL-21. IL-7 is mainly secreted by stroma cells in primary lymphoid tissues, playing an essential role in the program of T cell development. Recently, studies have revealed that physiological function exerted by immunocytes can be influenced by aberrant IL-7 signaling, which is common in abnormal autoimmunity regulation. There is also increasing evidence that IL-7 is involved in several autoimmune diseases, such as rheumatoid arthritis, type I diabetes, multiple sclerosis and systemic lupus erythematosus, etc. Targeting components in IL-7 signaling pathways may have potential significance for treating numerous autoimmune diseases. In this review, we therefore summarize our current understandings regarding the relationship between IL-7 and autoimmune diseases so as to render more valuable information on this kind of research.

Bikker A, Hack CE, Lafeber FP, van Roon JA (2012) Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction. Curr Pharm Des 18(16):2347–2356PubMedCrossRef

van Roon JA, Verweij MC, Wijk MW et al (2005) Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum 52(6):1700–1710PubMedCrossRef

Harrison C (2012) Autoimmune disease: targeting IL-7 reverses type 1 diabetes. Nat Rev Drug Discov 11(8):599PubMedCrossRef

Liu X, Leung S, Wang C et al (2010) Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 16(2):191–197PubMedCrossRef

Gregory SG, Schmidt S, Seth P et al (2007) Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39(9):1083–1091PubMedCrossRef

Badot V, Luijten RK, van Roon JA et al (2013) Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus. Ann Rheum Dis 72(3):453–456PubMedCrossRef

Lundström W, Highfill S, Walsh ST et al (2013) Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A 110(19):E1761–E1770PubMedCrossRef

Pillai M, Torok-Storb B, Iwata M (2004) Expression and function of IL-7 receptors in marrow stromal cells. Leuk Lymphoma 45(12):2403–2408PubMedCrossRef

McElroy CA, Dohm JA, Walsh ST (2009) Structural and biophysical studies of the human IL-7/IL-7Ralpha complex. Structure 17(1):54–65PubMedCrossRef

10.

Ceredig R, Rolink AG (2012) The key role of IL-7 in lymphopoiesis. Semin Immunol 24(3):159–164PubMedCrossRef

11.

Hong C, Luckey MA, Park J-H (2012) Intrathymic IL-7: the where, when, and why of IL-7 signaling during T cell development. Semin Immunol 24(3):151–158PubMedCrossRef

12.

Jiang Q, Huang J, Li WQ et al (2007) Role of the intracellular domain of IL-7 receptor in T cell development. J Immunol 178(1):228–234PubMed

13.

Mazzucchelli R, Durum SK (2007) Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7(2):144–154PubMedCrossRef

14.

Rose T, Pillet AH, Lavergne V et al (2010) Interleukin-7 compartmentalizes its receptor signaling complex to initiate CD4 T lymphocyte response. J Biol Chem 285(20):14898–14908PubMedCrossRef

15.

Benbernou N, Muegge K, Durum SK (2000) Interleukin (IL)-7 induces rapid activation of Pyk2, which is bound to Janus kinase 1 and IL-7Ralpha. J Biol Chem 275(10):7060–7065PubMedCrossRef

16.

Quintas-Cardama A, Verstovsek S (2013) Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 19(8):1933–1940PubMedCrossRef

17.

Palmer MJ, Mahajan VS, Trajman LC et al (2008) Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol 5(2):79–89PubMedCrossRef

18.

Jiang Q, Li WQ, Aiello FB et al (2005) Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16(4–5):513–533PubMedCrossRef

19.

Ivashkiv LB, Hu X (2004) Signaling by STATs. Arthritis Res Ther 6(4):159–168PubMedCrossRef

20.

Corfe SA, Paige CJ (2012) The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol 24(3):198–208PubMedCrossRef

21.

Smyth CM, Ginn SL, Deakin CT et al (2007) Limiting {gamma}c expression differentially affects signaling via the interleukin IL-7 and IL-15 receptors. Blood 110(1):91–98PubMedCrossRef

22.

Carrette F, Surh CD (2012) IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol 24(3):209–217PubMedCrossRef

23.

Boyman O, Ramsey C, Kim DM, Sprent J et al (2008) IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T Cell expansion without lymphopenia. J Immunol 180(11):7265–7275PubMed

24.

El-Kassar N, Flomerfelt FA, Choudhury B et al (2012) High levels of IL-7 cause dysregulation of thymocyte development. Int Immunol 24(10):661–671PubMedCrossRef

25.

Milne CD, Paige CJ (2006) IL-7: a key regulator of B lymphopoiesis. Semin Immunol 18(1):20–30PubMedCrossRef

26.

Akashi K, Kondo M, von Freeden-Jeffry U et al (1997) Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89(7):1033–1041PubMedCrossRef

27.

Malin S, McManus S, Busslinger M (2010) STAT5 in B cell development and leukemia. Curr Opin Immunol 22(2):168–176PubMedCrossRef

28.

Holm AM, Aukrust P, Damås JK, Müller F et al (2005) Abnormal interleukin-7 function in common variable immunodeficiency. Blood 105(7):2887–2890PubMedCrossRef

29.

Lundstrom W, Fewkes NM, Mackall CL (2012) IL-7 in human health and disease. Semin Immunol 24(3):218–224PubMedCrossRef

30.

Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39(7):857–864PubMedCrossRef

31.

Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356–361PubMedCrossRef

32.

Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1):233–255PubMedCrossRef

33.

Fry TJ, Mackall CL (2002) Interleukin-7: from bench to clinic. Blood 99(11):3892–3904PubMedCrossRef

34.

van Amelsfort JM, van Roon JA, Noordegraaf M et al (2007) Proinflammatory mediator-induced reversal of CD4+, CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 56(3):732–742PubMedCrossRef

35.

Churchman SM, Ponchel F (2008) Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford) 47(6):753–759CrossRef

36.

Natsumeda M, Nishiya K, Ota Z (1993) Stimulation by interleukin-7 of mononuclear cells in peripheral blood, synovial fluid and synovial tissue from patients with rheumatoid arthritis. Acta Med Okayama 47(6):391–397PubMed

37.

Sawa S, Kamimura D, Jin GH et al (2006) Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med 203(6):1459–1470PubMedCrossRef

38.

Harada S, Yamamura M, Okamoto H et al (1999) Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 42(7):1508–1516PubMedCrossRef

39.

van Roon JA, Glaudemans KA, Bijlsma JW et al (2003) Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(2):113–119PubMedCrossRef

40.

Pickens SR, Chamberlain ND, Volin MV et al (2011) Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 63(10):2884–2893PubMedCrossRef

41.

Rekha P, Conaghan PG, Paul E et al (2012) Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels. Ann Rheum Dis 72(6):1032–1036

42.

Makino T, Fukushima S, Wakasugi S et al (2009) Decreased serum IL-7 levels in patients with systemic sclerosis. Clin Exp Rheumatol 27(3 Suppl 54):68–69PubMed

43.

Kader HA, Tchernev VT, Satyaraj E et al (2005) Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 100(2):414–423PubMedCrossRef

44.

Lee LF, Logronio K, Tu GH et al (2012) Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A 109(31):12674–12679PubMedCrossRef

45.

Maahs DM, West NA, Lawrence JM et al (2010) Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 39(3):481–497PubMedCrossRef

46.

Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23:447–485PubMedCrossRef

47.

Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464(7293):1293–1300PubMedCrossRef

48.

Lee LF, Axtell R, Tu GH et al (2011) IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med 3(93):93ra68PubMedCrossRef

49.

Penaranda C, Kuswanto W, Hofmann J et al (2012) IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A 109(31):12668–12673PubMedCrossRef

50.

Keir ME, Liang SC, Guleria I et al (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883–895PubMedCrossRef

51.

Hafler DA (2004) Multiple sclerosis. J Clin Invest 113(6):788–794PubMed

52.

McFarlin DE, McFarland HF (1982) Multiple sclerosis (first of two parts). N Engl J Med 307(19):1183–1188PubMedCrossRef

53.

McFarlin DE, McFarland HF (1982) Multiple sclerosis (second of two parts). N Engl J Med 307(20):1246–1251PubMedCrossRef

54.

Fernald GH, Yeh RF, Hauser SL et al (2005) Mapping gene activity in complex disorders: Integration of expression and genomic scans for multiple sclerosis. J Neuroimmunol 167(1–2):157–169PubMedCrossRef

55.

Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683–747PubMedCrossRef

56.

Kreft KL, Verbraak E, Wierenga-Wolf AF et al (2012) Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients. Genes Immun 13(7):587–592PubMedCrossRef

57.

Walline CC, Kanakasabai S, Bright JJ (2011) IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis. Genes Immun 12(1):1–14PubMedCrossRef

58.

Lock C, Hermans G, Pedotti R et al (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8(5):500–508PubMedCrossRef

59.

McGeachy MJ, Chen Y, Tato CM et al (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10(3):314–324PubMedCrossRef

60.

Chen Y, Langrish CL, McKenzie B et al (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116(5):1317–1326PubMedCrossRef

61.

Tiffin N, Adeyemo A, Okpechi I (2013) A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J Rare Dis 8(1):2PubMedCrossRef

62.

Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121PubMedCrossRef

63.

Pons-Estel GJ, Alarcón GS, Scofield L et al (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257–268PubMedCrossRef

64.

Pan HF, Ye DQ, Li XP (2008) Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4(7):352–353PubMed

65.

Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011:432595PubMedCrossRef

66.

Ambrosi A, Espinosa A, Wahren-Herlenius M (2012) IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 42(9):2274–2284PubMedCrossRef

67.

Yang Y, Xiao X, Li F et al (2012) Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 53(2):1012–1017PubMedCrossRef

68.

Bikker A, Moret FM, Kruize AA et al (2012) IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford) 51(6):996–1005CrossRef

69.

Ben-David H, Sharabi A, Parameswaran R et al (2009) A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis. Immunology 128(2):245–252PubMedCrossRef

Titel: Perspectives of the relationship between IL-7 and autoimmune diseases
verfasst von: Xiao-Song Wang
Bao-Zhu Li
Lin-Feng Hu
Peng-Fei Wen
Min Zhang
Hai-Feng Pan
Dong-Qing Ye
Publikationsdatum: 01.12.2013
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 12/2013
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-013-2360-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Perspectives of the relationship between IL-7 and autoimmune diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial

A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis

Safety of joint and soft tissue injections in patients on warfarin anticoagulation

A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

High-dose methylprednisolone pulse therapy upregulated FcγRIIb expression on B cells in primary Sjögren’s syndrome patients with thrombocytopenia

Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin